Latest

Trackers› Clinical trials› Taunton

Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Taunton, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:15 UTC

2853

Studies in scope

industry-sponsored, all four open statuses

1387

Recruiting now

open to new participants

544

Lead sponsors

across recruiting studies

Top sites

London 137 Manchester 73 Cambridge 64 Glasgow 35 Edinburgh 34

Narrow the registerReset

Search within results

Recruitment status

Phase

Lead sponsor

Clear sponsor filter

Site city

All 136 cities

Target enrolment

to

Trials with a site in Taunton

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Carboplatin·Pembrolizumab

AstraZeneca

Phase 3

600

Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton

2025-03-27

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsCamizestrant·Saruparib·Anastrozole·Exemestane

AstraZeneca

Phase 3

788

Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro

2024-08-01

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Cambridge, London, Manchester, Oxford, Taunton

2024-03-04

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Olaparib·Doxorubicin

AstraZeneca

Phase 3

1,902

Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton

2023-11-14

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Ipilimumab·Nivolumab·Pemetrexed

AstraZeneca

Phase 3

863

Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton

2023-11-09

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib

AstraZeneca

Phase 3

893

Guildford, London, Londonderry, Taunton, York

2021-05-10

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsTaxane·Pertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Edinburgh, Guildford, London, Manchester, Swansea, Taunton

2021-04-26

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

AstraZeneca

Phase 3

185

Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton

2020-08-04

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton

2018-05-14

Active, closed

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293Non Small Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Gemcitabine·Pemetrexed

AstraZeneca

Phase 3

953

Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton

2015-11-03

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-uk/city/taunton

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies with a site in Taunton that also match the filters currently applied.

How many clinical trials are recruiting in Taunton?

2 of the 10 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Taunton), 10 studies
Phase	Studies	Recruiting	Share
Phase 3	10	2	100%

Most active sponsors

Lead sponsors with the most studies (Taunton)
Lead sponsor	Studies	Recruiting
AstraZeneca	10	2

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.